Cargando…

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Shinsuke, Toyoma, Satoshi, Kawasaki, Yohei, Koizumi, Koh, Iikawa, Nobuko, Shiina, Kazuhiro, Endo, Tentaro, Abe, Tomoe, Kouga, Teppei, Yamada, Takechiyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621992/
https://www.ncbi.nlm.nih.gov/pubmed/34833369
http://dx.doi.org/10.3390/medicina57111151
_version_ 1784605588886388736
author Suzuki, Shinsuke
Toyoma, Satoshi
Kawasaki, Yohei
Koizumi, Koh
Iikawa, Nobuko
Shiina, Kazuhiro
Endo, Tentaro
Abe, Tomoe
Kouga, Teppei
Yamada, Takechiyo
author_facet Suzuki, Shinsuke
Toyoma, Satoshi
Kawasaki, Yohei
Koizumi, Koh
Iikawa, Nobuko
Shiina, Kazuhiro
Endo, Tentaro
Abe, Tomoe
Kouga, Teppei
Yamada, Takechiyo
author_sort Suzuki, Shinsuke
collection PubMed
description Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This study aimed to evaluate the efficacy and safety of chemotherapy after immune checkpoint inhibitor administration in recurrent metastatic head and neck cancer by focusing on a single regimen. Materials and Methods: We retrospectively reviewed clinical and radiological data from the medical records of 18 patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab and paclitaxel (Cmab + PTX) after progression following immune checkpoint inhibitor (ICI) therapy. The objective response rate (ORR) and disease control rate (DCR) were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Adverse events (AEs) were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: In all patients, the ORR, DCR, median PFS, and median OS were 44.4%, 72.2%, 3.8 months, and 9.6 months, respectively. Regarding AEs, three patients developed grade 3 neutropenia. Grade 3 anemia, paronychia, asthenia, and peripheral neuropathy were observed in one patient each. There were no treatment-related deaths. Conclusions: Cmab + PTX was shown to maintain high efficacy and acceptable safety for R/M HNSCC that progressed after ICI therapy. Further research is needed to establish optimal treatment sequences and drug combinations for recurrent R/M HNSCC.
format Online
Article
Text
id pubmed-8621992
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86219922021-11-27 Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Suzuki, Shinsuke Toyoma, Satoshi Kawasaki, Yohei Koizumi, Koh Iikawa, Nobuko Shiina, Kazuhiro Endo, Tentaro Abe, Tomoe Kouga, Teppei Yamada, Takechiyo Medicina (Kaunas) Article Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This study aimed to evaluate the efficacy and safety of chemotherapy after immune checkpoint inhibitor administration in recurrent metastatic head and neck cancer by focusing on a single regimen. Materials and Methods: We retrospectively reviewed clinical and radiological data from the medical records of 18 patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab and paclitaxel (Cmab + PTX) after progression following immune checkpoint inhibitor (ICI) therapy. The objective response rate (ORR) and disease control rate (DCR) were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Adverse events (AEs) were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: In all patients, the ORR, DCR, median PFS, and median OS were 44.4%, 72.2%, 3.8 months, and 9.6 months, respectively. Regarding AEs, three patients developed grade 3 neutropenia. Grade 3 anemia, paronychia, asthenia, and peripheral neuropathy were observed in one patient each. There were no treatment-related deaths. Conclusions: Cmab + PTX was shown to maintain high efficacy and acceptable safety for R/M HNSCC that progressed after ICI therapy. Further research is needed to establish optimal treatment sequences and drug combinations for recurrent R/M HNSCC. MDPI 2021-10-23 /pmc/articles/PMC8621992/ /pubmed/34833369 http://dx.doi.org/10.3390/medicina57111151 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Suzuki, Shinsuke
Toyoma, Satoshi
Kawasaki, Yohei
Koizumi, Koh
Iikawa, Nobuko
Shiina, Kazuhiro
Endo, Tentaro
Abe, Tomoe
Kouga, Teppei
Yamada, Takechiyo
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_full Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_fullStr Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_full_unstemmed Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_short Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
title_sort clinical outcomes of cetuximab and paclitaxel after progression on immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621992/
https://www.ncbi.nlm.nih.gov/pubmed/34833369
http://dx.doi.org/10.3390/medicina57111151
work_keys_str_mv AT suzukishinsuke clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT toyomasatoshi clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT kawasakiyohei clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT koizumikoh clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT iikawanobuko clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT shiinakazuhiro clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT endotentaro clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT abetomoe clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT kougateppei clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma
AT yamadatakechiyo clinicaloutcomesofcetuximabandpaclitaxelafterprogressiononimmunecheckpointinhibitorsinrecurrentormetastaticheadandnecksquamouscellcarcinoma